Differences between in vivo and in vitro sensitivity to imatinib of Bcr/Abl+ cells obtained from leukemic patients

Blood Cells, Molecules, and Diseases

Volumn 28, Issue 3, 2002, Pages 361-372

  Gambacorti Passerini, Carlo B ^a,b   Rossi, Francesca ^a   Verga, Magda ^b   Ruchatz, Holger ^a   Gunby, Rosalind ^a   Frapolli, Roberta ^c   Zucchetti, Massimo ^c   Scapozza, Leonardo ^d   Bungaro, Silvia ^a,b   Tornaghi, Lucia ^a,b   Rossi, Fabio ^b   Pioltelli, Pietro ^b   Pogliani, Enrico ^b   D’incalci, Maurizio ^c   Corneo, Gianmarco ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b SAN GERARDO HOSPITAL   (Italy)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; ERYTHROMYCIN; IMATINIB; OROSOMUCOID; PROTEIN KINASE;

APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG INHIBITION; DRUG RESISTANCE; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; MYELOID LEUKEMIA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

EID: 0036431559     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1006/bcmd.2002.0526     Document Type: Article

References (27)

1. Sausville, E. A. (1999) A Bcr/Abl kinase antagonist for chronic myelogenous leukemia: A promising path for progress emerges [editorial; comment]. J. Natl. Cancer Inst. 91, 102-103.
2. Sawyers, C. L. (1999) Chronic myeloid leukemia. N. Engl. J. Med. 340, 1330-1340.
3. Cortez, D., Kadlec, L., and Pendergast, A. M. (1995) Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis. Mol. Cell. Biol. 15, 5531-5541.
4. Goga, A., McLaughlin, J., Afar, D. E., Saffran, D. C., and Witte, O. N. (1995) Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene. Cell 82, 981-988.
5. Druker, B. J., Tamura, S., Buchdunger, E., et al. (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2, 561-566.
6. Gambacorti-Passerini, C., le Coutre, P., Mologni, L., et al. (1997) Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol. Dis. 23, 380-394.
7. Deininger, M. W., Goldman, J. M., Lydon, N., and Melo, J. V. (1997) The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 90, 3691-3698.
8. le Coutre, P., Mologni, L., Cleris, L., et al. (1999) In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J. Natl. Cancer Inst. 91, 163-168.
9. Druker, B. J., Sawyers, C. L., Kantarjian, H., et al. (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344, 1038-1042.
10. Druker, B. J., Talpaz, M., Resta, D. J., et al. (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031-1037.
11. Talpaz, M., Silver, R. T., Druker, B., et al. (2001) Glivec (imatinib mesylate) induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Result of a phase II study. Blood, in press.
12. le Coutre, P., Tassi, E., Varella-Garcia, M., et al. (2000) Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 95, 1758-1766.
13. Weisberg, E., and Griffin, J. D. (2000) Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood 95, 3498-3505.
14. Mahon, F. X., Deininger, M. W., Schultheis, B., et al. (2000) Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: Diverse mechanisms of resistance. Blood 96, 1070-1079.
15. Gorre, M. E., Mohammed, M., Ellwood, K., et al. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876-880.
16. Gambacorti-Passerini, C., Barni, R., le Coutre, P., et al. (2000) Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571. J. Natl. Cancer Inst. 92, 1641-1650.
17. Goldman, J. M., and Druker, B. J. (2001) Chronic myeloid leukemia: Current treatment options. Blood 98, 2039-2042.
18. Gambacorti-Passerini, C., Corneo, G., and D'Incalci, M. (2001) Roots of clinical resistance to STI-571 cancer therapy. Science 293, 2163.
19. Larghero, J., Mahon, F., Madalaine-Chambrin, I., et al. (2001) Elevated levels of the plasma protein alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis mediate pharmacological resistance to Gleevec (STI571, imatinib) in vitro and are associated with primary resistance in vivo. American Society of Hematology, 43th Annual Meeting, Orlando, Florida. Blood 98, 616a n, 2582.
20. le Coutre, P., Kreuzer, K., Na, I., et al. (2002) Determination of α1 acid glycoprotein in patients with Ph+ chronic myeloid leukemia during the first 13 weeks of therapy with STI571. Blood Cells Mol. Dis. 28, 75-85.
21. Hochhaus, A., Kreil, S., Corbin, A., et al. (2001) Roots of clinical resistance to STI-571 cancer therapy. Science 293, 2163.
22. Barthe, C., Cony-Makhoul, P., Melo, J. V., and Mahon, J. R. (2001) Roots of clinical resistance to STI-571 cancer therapy. Science 293, 2163.
23. Dorsey, J. F., Jove, R., Kraker, A. J., and Wu, J. (2000) The pyrido[2, 3-d]pyrimidine derivative PD180970 inhibits p210Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells. Cancer Res. 60, 3127-3131.
24. von Bubnoff, N., Schneller, F., Peschel, C., and Duyster, J. (2002) BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: A prospective study. Lancet 359(9305), 487-491.
25. Branford, S., Rudzki, Z., Walsh, S., et al. (2002) High frequency of point mutation clustered within the ATP binding region of BCR/ABL in CML and Ph-positive ALL patients who develop Imatinib (STI57) resistance. Blood 99(9), 3472-3475.
26. Jorgensen, H. G., Elliott, M. A., Allan, E. K., Carr, C. E., Holyoake, T. L., and Smith, K. D. (2002) alpha(1)-Acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571. Blood 99, 713-715.
27. Gambacorti-Passerini, C., le Coutre, P., Zucchetti, M., and D'Incalci, M. (2002) Binding of imatinib by alpha 1 acid glycoprotein. Blood 100, in press.